Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus

Nicholas H Varvel1, Claudia Espinosa-Garcia2, Sarah Hunter-Chang2

  • 1Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia 30322 nvarvel@emory.edu.

Insights

Targeting EP2 receptors on peripheral immune cells can mitigate negative effects of seizures, such as inflammation and behavioral deficits. This research highlights the role of these receptors in immune cells in driving seizure-induced brain damage.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Status epilepticus (SE) triggers a complex inflammatory response involving prostaglandin EP2 receptors.
  • Previous research indicated that inhibiting EP2 receptors or monocyte infiltration alleviates SE consequences.

Purpose of the Study:

  • To determine the specific cell types expressing EP2 receptors responsible for SE-induced inflammation and damage.
  • To investigate whether conditional ablation of EP2 receptors in immune myeloid cells mimics the effects of systemic EP2 antagonism.

Main Methods:

  • Utilized a pilocarpine-induced status epilepticus (SE) mouse model.
  • Generated myeloid-specific EP2 receptor conditional knockout (KO) mice.
  • Assessed inflammatory markers (IL-6), blood-brain barrier (BBB) integrity (serum albumin), and behavioral recovery.

Main Results:

  • Conditional ablation of EP2 receptors in myeloid cells reduced IL-6 induction and BBB breakdown post-SE.
  • EP2 deficiency in innate immune cells accelerated recovery from sickness behaviors.
  • Systemic EP2 antagonism provided broader neuroprotection and suppressed more inflammatory mediators than myeloid-specific ablation.

Conclusions:

  • Activation of EP2 receptors on peripheral immune myeloid cells contributes significantly to behavioral deficits and BBB disruption after SE.
  • Systemic EP2 antagonism offers therapeutic benefits by blocking monocyte infiltration into the brain.
  • Targeting EP2 receptors on peripheral immune cells presents a promising therapeutic strategy for managing SE consequences.